{"id":"https://openalex.org/W2962945166","doi":"https://doi.org/10.1007/s40262-019-00804-x","title":"Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies","display_name":"Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies","publication_year":2019,"publication_date":"2019-07-22","ids":{"openalex":"https://openalex.org/W2962945166","doi":"https://doi.org/10.1007/s40262-019-00804-x","mag":"2962945166","pmid":"https://pubmed.ncbi.nlm.nih.gov/31332669","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7007418"},"language":"en","primary_location":{"id":"doi:10.1007/s40262-019-00804-x","doi":"https://doi.org/10.1007/s40262-019-00804-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-019-00804-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-019-00804-x.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40262-019-00804-x.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059141673","display_name":"Ken Ogasawara","orcid":"https://orcid.org/0000-0002-4264-8927","observed_orcids":["https://orcid.org/0000-0002-4264-8927"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ken Ogasawara","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":"https://orcid.org/0000-0002-4264-8927","affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029020612","display_name":"Kathryn J. Newhall","orcid":"https://orcid.org/0000-0002-6441-9316","observed_orcids":["https://orcid.org/0000-0002-6441-9316"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathryn Newhall","raw_affiliation_strings":["Celgene Corporation, Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Seattle, WA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103088902","display_name":"Stephen E. Maxwell","orcid":"https://orcid.org/0000-0001-7079-3681","observed_orcids":["https://orcid.org/0000-0001-7079-3681"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen E. Maxwell","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054145913","display_name":"Justine Dell\u2019Aringa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Justine Dell\u2019Aringa","raw_affiliation_strings":["Celgene Corporation, Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Seattle, WA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082490975","display_name":"Vitalina Komashko","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vitalina Komashko","raw_affiliation_strings":["Celgene Corporation, Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Seattle, WA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082078478","display_name":"Nurgul Kilavuz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nurgul Kilavuz","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014942120","display_name":"Richard Delarue","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387154805","display_name":"Celgene (Switzerland)","ror":"https://ror.org/055503602","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387154805"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Richard Delarue","raw_affiliation_strings":["Celgene Corporation, Boudry, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Boudry, Switzerland","institution_ids":["https://openalex.org/I4387154805"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110554446","display_name":"Myron Stefan Czuczman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Myron Czuczman","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029390766","display_name":"Lars Axel Sternas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lars Sternas","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112451928","display_name":"Shelonitda Rose","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shelonitda Rose","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111831270","display_name":"C. L. Beach","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. L. Beach","raw_affiliation_strings":["Celgene Corporation, Kansas City, KS, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Kansas City, KS, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042841642","display_name":"Steven J. Novick","orcid":"https://orcid.org/0000-0001-8760-1519","observed_orcids":["https://orcid.org/0000-0001-8760-1519"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Novick","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109036817","display_name":"Simon Yuji Zhou","orcid":"https://orcid.org/0000-0003-4688-3307","observed_orcids":["https://orcid.org/0000-0003-4688-3307"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Simon Zhou","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042912939","display_name":"Maria Palmisano","orcid":"https://orcid.org/0000-0003-1518-5688","observed_orcids":["https://orcid.org/0000-0003-1518-5688"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria Palmisano","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100711754","display_name":"Yan Li","orcid":"https://orcid.org/0000-0001-7609-2683","observed_orcids":["https://orcid.org/0000-0001-7609-2683"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Yan Li","raw_affiliation_strings":["Celgene Corporation, Summit, NJ, USA. yali@celgene.com","Celgene Corporation, Summit, NJ, USA"],"raw_orcid":"https://orcid.org/0000-0001-7609-2683","affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA. yali@celgene.com","institution_ids":["https://openalex.org/I4387155837"]},{"raw_affiliation_string":"Celgene Corporation, Summit, NJ, USA","institution_ids":["https://openalex.org/I4387155837"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5100711754"],"corresponding_institution_ids":["https://openalex.org/I4387155837"],"apc_list":{"value":3760,"currency":"USD","value_usd":3760},"apc_paid":{"value":3760,"currency":"USD","value_usd":3760},"fwci":2.1343,"has_fulltext":true,"cited_by_count":31,"citation_normalized_percentile":{"value":0.89116721,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":99},"biblio":{"volume":"59","issue":"2","first_page":"217","last_page":"227"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8154000043869019,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8154000043869019,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.14839999377727509,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.005200000014156103,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":1.0},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.8379999995231628},{"id":"https://openalex.org/keywords/population-pharmacokinetics","display_name":"population pharmacokinetics","score":0.9139999747276306},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.9980000257492065},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9649999737739563},{"id":"https://openalex.org/keywords/igg","display_name":"IgG","score":0.9259999990463257},{"id":"https://openalex.org/keywords/albumin-binding","display_name":"albumin binding","score":0.8119999766349792},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.746999979019165},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.6620000004768372},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9390000104904175},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9179999828338623},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.9869999885559082},{"id":"https://openalex.org/keywords/hodgkin-lymphoma","display_name":"Hodgkin's disease","score":0.9990000128746033}],"concepts":[{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.9772031307220459},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7848201990127563},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7656936645507812},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6596736907958984},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5062152743339539},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4634966552257538},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.40905895829200745},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3873419761657715},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3715255558490753},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3356549143791199},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.15218982100486755},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.09705975651741028},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000418","descriptor_name":"Albumins","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D000418","descriptor_name":"Albumins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D007074","descriptor_name":"Immunoglobulin G","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008228","descriptor_name":"Lymphoma, Non-Hodgkin","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008228","descriptor_name":"Lymphoma, Non-Hodgkin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009190","descriptor_name":"Myelodysplastic Syndromes","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009190","descriptor_name":"Myelodysplastic Syndromes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000208","qualifier_name":"ethnology","is_major_topic":false},{"descriptor_ui":"D019337","descriptor_name":"Hematologic Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1007/s40262-019-00804-x","doi":"https://doi.org/10.1007/s40262-019-00804-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-019-00804-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-019-00804-x.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},{"id":"pmid:31332669","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31332669","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacokinetics","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7007418","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7007418/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacokinet","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1007/s40262-019-00804-x","doi":"https://doi.org/10.1007/s40262-019-00804-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-019-00804-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-019-00804-x.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2962945166.pdf","grobid_xml":"https://content.openalex.org/works/W2962945166.grobid-xml"},"referenced_works_count":17,"referenced_works":["https://openalex.org/W1913780655","https://openalex.org/W2123176392","https://openalex.org/W2135305016","https://openalex.org/W2551291014","https://openalex.org/W2554947920","https://openalex.org/W2564934728","https://openalex.org/W2567068937","https://openalex.org/W2587297698","https://openalex.org/W2587635492","https://openalex.org/W2620733650","https://openalex.org/W2630105953","https://openalex.org/W2740280053","https://openalex.org/W2754555242","https://openalex.org/W2775344839","https://openalex.org/W2895957341","https://openalex.org/W2915034229","https://openalex.org/W2937892484"],"related_works":["https://openalex.org/W2685961074","https://openalex.org/W2775344839","https://openalex.org/W2584856244","https://openalex.org/W4310497577","https://openalex.org/W4322616597","https://openalex.org/W7214670954","https://openalex.org/W3212885064","https://openalex.org/W2898813265","https://openalex.org/W2740280053","https://openalex.org/W2630105953"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1],"OBJECTIVES:":[2],"Durvalumab,":[3],"a":[4,49,112,160,246],"human":[5],"monoclonal":[6,253],"antibody":[7],"targeting":[8],"programmed":[9],"cell":[10,24],"death":[11],"ligand":[12],"1,":[13],"has":[14],"been":[15],"approved":[16],"for":[17,226,249],"urothelial":[18],"carcinoma":[19],"and":[20,31,34,60,67,138,230],"stage":[21],"III":[22],"non-small":[23],"lung":[25],"cancer":[26],"by":[27,111,128],"the":[28,63,71,101,147,165,217,234,250],"US":[29],"Food":[30],"Drug":[32],"Administration":[33],"is":[35],"being":[36],"evaluated":[37],"in":[38,54,73,100,120,133,200,210,255],"various":[39,57],"malignancies.":[40],"The":[41,104,180,196],"objective":[42],"of":[43,52,65,79,106,130,182,198,236,252],"this":[44,74],"study":[45],"was":[46,108,125,203],"to":[47,61,192],"develop":[48],"population-pharmacokinetic":[50],"model":[51,114],"durvalumab":[53,107,121,187,199],"patients":[55,84,142,152,173,256],"with":[56,85,115,143,153,172,174,206,257],"hematologic":[58,201,231],"malignancies":[59,202,232],"investigate":[62],"effects":[64],"demographic":[66],"disease":[68],"factors":[69],"on":[70,186],"pharmacokinetics":[72,105,188,197,209,251],"population.":[75],"METHODS:":[76],"A":[77,118],"total":[78,240],"1812":[80],"concentrations":[81],"from":[82,233],"267":[83],"myelodysplastic":[86],"syndromes,":[87],"acute":[88],"myeloid":[89],"leukemia,":[90],"multiple":[91,144,150,258],"myeloma,":[92,151],"non-Hodgkin":[93],"lymphoma,":[94],"or":[95],"Hodgkin":[96],"lymphoma":[97],"were":[98],"included":[99],"analysis.":[102],"RESULTS:":[103],"adequately":[109],"described":[110],"two-compartment":[113],"first-order":[116],"elimination.":[117],"decrease":[119],"clearance":[122],"over":[123],"time":[124],"mainly":[126],"explained":[127],"incorporation":[129],"time-dependent":[131],"changes":[132],"albumin":[134],"(in":[135,141],"all":[136],"patients)":[137],"immunoglobulin":[139,154,175,241],"G":[140,155,176,242],"myeloma)":[145],"into":[146],"model.":[148],"For":[149],"\u2265":[156],"20":[157,178],"g/L":[158],"showed":[159],"30%":[161],"lower":[162],"area":[163],"under":[164],"concentration-time":[166],"curve":[167],"at":[168],"cycle":[169],"1":[170],"compared":[171],"<":[177],"g/L.":[179],"impact":[181],"any":[183],"baseline":[184],"covariates":[185],"did":[189],"not":[190],"appear":[191],"be":[193,245],"clinically":[194],"relevant.":[195],"generally":[204],"consistent":[205],"previously":[207],"reported":[208],"solid":[211,228],"tumors.":[212],"CONCLUSIONS:":[213],"These":[214],"results":[215],"support":[216],"same":[218],"dosing":[219],"regimen":[220],"(1500":[221],"mg":[222],"every":[223],"4":[224],"weeks)":[225],"both":[227],"tumors":[229],"perspective":[235],"adequate":[237],"exposure.":[238],"Additionally,":[239],"level":[243],"could":[244],"critical":[247],"covariate":[248],"antibodies":[254],"myeloma.":[259]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2019-07-30T00:00:00"}